series	seriesDescription	geoAreaCode	geoAreaName	timePeriodStart	value	valueType	time_detail	upperBound	lowerBound	basePeriod	source	footnotes	Nature	Units	Reporting Type
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	140	Central African Republic	2011.0	8	Float					WHO/UNICEF coverage estimates 2017 revision, July 2018	['']	E	PERCENT	G
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	140	Central African Republic	2012.0	47	Float					WHO/UNICEF coverage estimates 2017 revision, July 2018	['']	E	PERCENT	G
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	140	Central African Republic	2013.0	23	Float					WHO/UNICEF coverage estimates 2017 revision, July 2018	['']	E	PERCENT	G
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	140	Central African Republic	2014.0	47	Float					WHO/UNICEF coverage estimates 2017 revision, July 2018	['']	E	PERCENT	G
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	140	Central African Republic	2015.0	47	Float					WHO/UNICEF coverage estimates 2017 revision, July 2018	['']	E	PERCENT	G
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	140	Central African Republic	2016.0	47	Float					WHO/UNICEF coverage estimates 2017 revision, July 2018	['']	E	PERCENT	G
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	140	Central African Republic	2017.0	47	Float					WHO/UNICEF coverage estimates 2017 revision, July 2018	['']	E	PERCENT	G
